0001817048-20-000001.txt : 20200722 0001817048-20-000001.hdr.sgml : 20200722 20200722121430 ACCESSION NUMBER: 0001817048-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200722 DATE AS OF CHANGE: 20200722 EFFECTIVENESS DATE: 20200722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gilgamesh Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001817048 IRS NUMBER: 842552195 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-371573 FILM NUMBER: 201040908 BUSINESS ADDRESS: STREET 1: 201 DAM TRAIL #1349 CITY: LINVILLE STATE: NC ZIP: 28646 BUSINESS PHONE: 347-967-6831 MAIL ADDRESS: STREET 1: 201 DAM TRAIL #1349 CITY: LINVILLE STATE: NC ZIP: 28646 D 1 primary_doc.xml X0708 D LIVE 0001817048 Gilgamesh Pharmaceuticals, Inc. 113 University Place Suite 1019 New York NY NEW YORK 10003 347-967-6831 DELAWARE None None Corporation true 2019 Jonathan Sporn, M.D. 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Director President and Chief Executive Officer Andrew Kruegel, Ph.D. 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Thomas Kevin Murphy, Ph.D. 113 University Place Suite 1019 New York NY NEW YORK 10003 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2020-07-21 false true Simple Agreement for Future Equity (SAFE), the equity securities of Issuer into which the SAFE may convert (Converted Securities), and the equity securities of Issuer into which the Converted Securities may convert. false 150000 150000 150000 0 false 1 0 0 0 false Gilgamesh Pharmaceuticals, Inc. Jonathan Sporn, M.D. /s/ Jonathan Sporn, M.D. President and Chief Executive Officer 2020-07-22